Your email has been successfully added to our mailing list.

×
-0.00275162925416362 0.00217523533671271 -0.00394496741491659 -0.00419985517740756 -0.0323215061549601 -0.060101375814627 -0.0705286024619839 -0.0650253439536567
Stock impact report

Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangioc...

Agios Pharmaceuticals, Inc. (AGIO) 
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.agios.com/investor-overview
Company Research Source: GlobeNewswire
– TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p® was 2.7 months Compared to 1.4 Months with Placebo – – TIBSOVO® Patients Had 6-month PFS Rate of 32% and 12-month PFS Rate of 22%; No Placebo Patients Were Free From Progression for More Than Six Months – – Supplemental New Drug Application on Track for Submission by End of 2019 – – Company to Host Conference Call and Webcast on Monday, September 30 at 1p.m. ET / 7p.m. CET – BARCELONA, Spain, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented data from the global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation in a Presidential Symposium at the European Society for Medical Oncology Congress (ESMO). Results from the ClarIDHy trial demonstrated a statistically significant im Show less Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
AGIO alerts

from News Quantified
Opt-in for
AGIO alerts

from News Quantified